Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?

被引：4

作者：

Aragon-Ching, Jeanny B. ^{[1
]}

机构：

[1] Inova Schar Canc Inst, Fairfax, VA 22031 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 25期

关键词：

ANDROGEN SUPPRESSION; RADIOTHERAPY; ESTRAMUSTINE; DOCETAXEL; THERAPY;

D O I：

10.1200/JCO.19.00977

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2296 / +

页数：3

共 9 条

[1] Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial [J].

Ahlgren, Goran M. ;

Flodgren, Per ;

Tammela, Teuvo L. J. ;

Kellokumpu-Lehtinen, Pirkko ;

Borre, Michael ;

Angelsen, Anders ;

Iversen, Jon Reidar ;

Sverrisdottir, Asgerdur ;

Jonsson, Eirikur ;

Sengelov, Lisa .

EUROPEAN UROLOGY, 2018, 73 (06) :870-876

[2]

Fizazi K, 2018, ANN ONCOL S, V29

[3] Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial [J].

Fizazi, Karim ;

Faivre, Laura ;

Lesaunier, Francois ;

Delva, Remy ;

Gravis, Gwenaelle ;

Rolland, Frederic ;

Priou, Frank ;

Ferrero, Jean-Marc ;

Houede, Nadine ;

Mourey, Loic ;

Theodore, Cnristine ;

Krakowski, Ivan ;

Berdah, Jean-Francois ;

Baciuchka, Marjorie ;

Laguerre, Brigitte ;

Flechon, Aude ;

Ravaud, Alain ;

Cojean-Zelek, Isabelle ;

Oudard, Stephane ;

Labourey, Jean-Luc ;

Chinet-Charrot, Paule ;

Legouffe, Eric ;

Lagrange, Jean-Leon ;

Linassier, Claude ;

Deplanque, Gael ;

Beuzeboc, Philippe ;

Davin, Jean-Louis ;

Martin, Anne-Laure ;

Habibian, Muriel ;

Laplanche, Agnes ;

Culine, Stephane .

LANCET ONCOLOGY, 2015, 16 (07) :787-794

[4] A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial. [J].

Kellokumpu-Lehtinen, Pirkko-Liisa Irmeli ;

Hjalm-Eriksson, Marie ;

Astrom, Lennart ;

Marttila, Timo ;

Thellenberg-Karlsson, Camilla ;

Nilsson, Sten ;

Anders, Widmark ;

Huttunen, Teppo ;

Ginman, Claes .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[5] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial [J].

Kyriakopoulos, Christos E. ;

Chen, Yu-Hui ;

Carducci, Michael A. ;

Liu, Glenn ;

Jarrard, David F. ;

Hahn, Noah M. ;

Shevrin, Daniel H. ;

Dreicer, Robert ;

Hussain, Maha ;

Eisenberger, Mario ;

Kohli, Manish ;

Plimack, Elizabeth R. ;

Vogelzang, Nicholas J. ;

Picus, Joel ;

Cooney, Matthew M. ;

Garcia, Jorge A. ;

DiPaola, Robert S. ;

Sweeney, Christopher J. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) :1080-+

[6] Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines [J].

Mohler, James L. ;

Armstrong, Andrew J. ;

Bahnson, Robert R. ;

D'Amico, Anthony Victor ;

Davis, Brian J. ;

Eastham, James A. ;

Enke, Charles A. ;

Farrington, Thomas A. ;

Higano, Celestia S. ;

Horwitz, Eric M. ;

Hurwitz, Michael ;

Kane, Christopher J. ;

Kawachi, Mark H. ;

Kuettel, Michael ;

Lee, Richard J. ;

Meeks, Joshua J. ;

Penson, David F. ;

Plimack, Elizabeth R. ;

Pow-Sang, Julio M. ;

Raben, David ;

Richey, Sylvia ;

Roach, Mack, III ;

Rosenfeld, Stan ;

Schaeffer, Edward ;

Skolarus, Ted A. ;

Small, Eric J. ;

Sonpavde, Guru ;

Srinivas, Sandy ;

Strope, Seth A. ;

Tward, Jonathan ;

Shead, Dorothy A. ;

Freedman-Cass, Deborah A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (01) :19-30

[7] Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial [J].

Rosenthal, Seth A. ;

Hu, Chen ;

Sartor, Oliver ;

Gomella, Leonard G. ;

Amin, Mahul B. ;

Purdy, James ;

Michalski, Jeff M. ;

Garzotto, Mark G. ;

Pervez, Nadeem ;

Balogh, Alexander G. ;

Rodrigues, George B. ;

Souhami, Luis ;

Reaume, M. Neil ;

Williams, Scott G. ;

Hannan, Raquibul ;

Horwitz, Eric M. ;

Raben, Adam ;

Peters, Christopher A. ;

Feng, Felix Y. ;

Shipley, William U. ;

Sandler, Howard M. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) :1159-+

[8] PHASE III MULTI-INSTITUTIONAL TRIAL OF ADJUVANT CHEMOTHERAPY WITH PACLITAXEL, ESTRAMUSTINE, AND ORAL ETOPOSIDE COMBINED WITH LONG-TERM ANDROGEN SUPPRESSION THERAPY AND RADIOTHERAPY VERSUS LONG-TERM ANDROGEN SUPPRESSION PLUS RADIOTHERAPY ALONE FOR HIGH-RISK PROSTATE CANCER: PRELIMINARY TOXICITY ANALYSIS OF RTOG 99-02 [J].

Rosenthal, Seth A. ;

Bae, Kyoungwha ;

Pienta, Kenneth J. ;

Sobczak, Mark L. ;

Asbell, Sucha O. ;

Rajan, Raghu ;

Kerlin, Kevin J. ;

Michalski, Jeff M. ;

Sandler, Howard M. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :672-678

[9] Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data [J].

Vale, Claire L. ;

Burdett, Sarah ;

Rydzewska, Larysa H. M. ;

Albiges, Laurence ;

Clarke, Noel W. ;

Fisher, David ;

Fizazi, Karim ;

Gravis, Gwenaelle ;

James, Nicholas D. ;

Mason, Malcolm D. ;

Parmar, Mahesh K. B. ;

Sweeney, Christopher J. ;

Sydes, Matthew R. ;

Tombal, Bertrand ;

Tierney, Jayne F. .

LANCET ONCOLOGY, 2016, 17 (02) :243-256

← 1 →